X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11713) 11713
Newsletter (90) 90
Magazine Article (85) 85
Book Chapter (30) 30
Newspaper Article (25) 25
Book / eBook (13) 13
Conference Proceeding (11) 11
Transcript (8) 8
Dissertation (6) 6
Publication (6) 6
Web Resource (6) 6
Reference (3) 3
Book Review (2) 2
Government Document (2) 2
Report (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9329) 9329
female (5317) 5317
folic acid (4263) 4263
folic acid - therapeutic use (4154) 4154
male (3600) 3600
adult (2697) 2697
animals (2286) 2286
middle aged (2168) 2168
pregnancy (2035) 2035
aged (1571) 1571
folic-acid (1448) 1448
cancer (1275) 1275
homocysteine (1253) 1253
folate (1237) 1237
dietary supplements (1208) 1208
risk factors (1205) 1205
folic acid antagonists - therapeutic use (1181) 1181
pharmacology & pharmacy (1148) 1148
folic acid - blood (1144) 1144
vitamin b (1088) 1088
folic acid - administration & dosage (1086) 1086
vitamin b 12 - therapeutic use (989) 989
homocysteine - blood (982) 982
mice (980) 980
adolescent (951) 951
health aspects (912) 912
folic acid - metabolism (893) 893
child (782) 782
research (782) 782
nanoparticles (781) 781
oncology (734) 734
treatment outcome (717) 717
vitamin b complex - therapeutic use (716) 716
prevention (673) 673
medicine, general & internal (669) 669
risk (656) 656
analysis (655) 655
methotrexate (654) 654
nutrition & dietetics (649) 649
neural tube defects - prevention & control (626) 626
folic acid - chemistry (609) 609
drug delivery systems (602) 602
care and treatment (601) 601
methotrexate - therapeutic use (577) 577
infant, newborn (576) 576
vitamin b 12 - blood (569) 569
chemotherapy (539) 539
drugs (535) 535
supplementation (535) 535
therapy (534) 534
cell line, tumor (521) 521
child, preschool (516) 516
metabolism (516) 516
diet (512) 512
infant (511) 511
folic acid - pharmacology (509) 509
rats (500) 500
neural-tube defects (470) 470
young adult (463) 463
physiological aspects (460) 460
prevalence (442) 442
tumors (439) 439
drug therapy, combination (429) 429
plasma homocysteine (429) 429
research article (419) 419
time factors (415) 415
pyrimidines - therapeutic use (414) 414
anemia (413) 413
iron - therapeutic use (411) 411
vitamins (411) 411
double-blind method (408) 408
clinical neurology (401) 401
medicine (399) 399
oxidative stress (397) 397
folic acid antagonists - pharmacology (392) 392
disease (391) 391
women (390) 390
folic acid deficiency - complications (389) 389
antineoplastic agents - therapeutic use (387) 387
hyperhomocysteinemia (387) 387
medicine & public health (387) 387
toxicity (387) 387
biochemistry & molecular biology (386) 386
neoplasms - drug therapy (386) 386
acids (383) 383
vitamin b12 (380) 380
nutrition (369) 369
in-vitro (367) 367
vitamins - therapeutic use (364) 364
sulfamethoxazole - therapeutic use (363) 363
pediatrics (358) 358
prospective studies (348) 348
drug-delivery (346) 346
methylenetetrahydrofolate reductase (346) 346
enzymes (345) 345
clinical trials as topic (344) 344
nanoscience & nanotechnology (343) 343
aged, 80 and over (335) 335
children (335) 335
cells (331) 331
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10925) 10925
German (333) 333
French (226) 226
Italian (144) 144
Spanish (122) 122
Russian (87) 87
Japanese (49) 49
Chinese (42) 42
Polish (40) 40
Dutch (36) 36
Portuguese (36) 36
Danish (17) 17
Hungarian (16) 16
Swedish (15) 15
Czech (13) 13
Norwegian (12) 12
Hebrew (9) 9
Bulgarian (8) 8
Romanian (7) 7
Finnish (5) 5
Persian (4) 4
Ukrainian (4) 4
Serbian (3) 3
Turkish (2) 2
Croatian (1) 1
Icelandic (1) 1
Korean (1) 1
Lithuanian (1) 1
Slovak (1) 1
Slovenian (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Treatment Reviews, ISSN 0305-7372, 2014, Volume 40, Issue 9, pp. 1080 - 1088
Highlights • PTCL has a poor prognosis; existing therapies are insufficient. • We summarize current evidence on novel therapies for relapsed/refractory PTCL. •... 
Hematology, Oncology and Palliative Medicine | Antifolate | Nucleoside analog | Histone deacetylase inhibitor | Fusion protein | Peripheral T-cell lymphoma | Immunomodulatory agent | DENILEUKIN DIFTITOX | NON-HODGKINS-LYMPHOMAS | FOLLOW-UP | BRENTUXIMAB VEDOTIN SGN-35 | OPEN-LABEL | ALLOGENEIC TRANSPLANTATION | SINGLE-AGENT | PHASE-II TRIAL | ONCOLOGY | SALVAGE THERAPY | HIGH-DOSE CHEMOTHERAPY | Doxorubicin - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Interleukin-2 - therapeutic use | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Cyclophosphamide - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Folic Acid Antagonists - therapeutic use | Stem Cell Transplantation | Topoisomerase Inhibitors - pharmacology | Thalidomide - analogs & derivatives | Diphtheria Toxin - therapeutic use | Topoisomerase Inhibitors - therapeutic use | Immunoconjugates - therapeutic use | Antineoplastic Agents - pharmacology | Depsipeptides - therapeutic use | Prednisolone - therapeutic use | Lymphoma, T-Cell, Peripheral - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Alemtuzumab | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Vincristine - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Lymphoma, T-Cell, Peripheral - therapy | Thalidomide - therapeutic use | Folic Acid Antagonists - pharmacology | Care and treatment | Lymphomas | T cells | Health aspects
Journal Article
Lancet neurology, ISSN 1474-4422, 2011, Volume 10, Issue 7, pp. 609 - 617
Journal Article
Journal Article
Cochrane library, ISSN 1465-1858, 2013, Volume 2014, Issue 7, p. CD000951
...). Pharmacologically, it is classified as an antimetabolite due to its antagonistic effect on folic acid metabolism... 
Folic Acid | Hematologic Diseases | Disease modifying antirheumatic drugs (DMARDs), also slow acting antirheumatic drugs; second line agents (SAARDs) | Folic Acid Antagonists | Rheumatology | Antirheumatic Agents | Abdominal Pain | Leucovorin | Nausea | Arthritis, Rheumatoid | DMARDS & SAARDS | Gastrointestinal Diseases | Complementary & alternative medicine | Vomiting | Rheumatoid arthritis | Treatment [Pharmacological interventions] | Methotrexate | Medicine General & Introductory Medical Sciences | LONG-TERM | Gastrointestinal Diseases [chemically induced; prevention & control] | LOW-DOSE METHOTREXATE | PLACEBO | EFFICACY | Humans | Folic Acid Antagonists [adverse effects; therapeutic use] | PULSE METHOTREXATE | Arthritis, Rheumatoid [drug therapy] | FOLATE SUPPLEMENTATION | TOXICITY | Hematologic Diseases [chemically induced; prevention & control] Leucovorin [therapeutic use] | MEDICINE, GENERAL & INTERNAL | Antirheumatic Agents [adverse effects; therapeutic use] | THERAPY | Folic Acid [therapeutic use] | 2ND-LINE DRUGS | DOUBLE-BLIND | Methotrexate [adverse effects; therapeutic use] | Hematologic Diseases - chemically induced | Leucovorin - administration & dosage | Abdominal Pain - chemically induced | Abdominal Pain - prevention & control | Folic Acid - therapeutic use | Nausea - chemically induced | Gastrointestinal Diseases - prevention & control | Methotrexate - therapeutic use | Folic Acid - administration & dosage | Folic Acid Antagonists - therapeutic use | Nausea - prevention & control | Methotrexate - adverse effects | Vomiting - chemically induced | Hematologic Diseases - prevention & control | Arthritis, Rheumatoid - drug therapy | Antirheumatic Agents - adverse effects | Adult | Leucovorin - therapeutic use | Folic Acid Antagonists - adverse effects | Vomiting - prevention & control | Gastrointestinal Diseases - chemically induced | Antirheumatic Agents - therapeutic use
Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 1460-2105, 2009, Volume 101, Issue 6, pp. 432 - 435
Journal Article
Journal Article
Journal Article
Asian Pacific journal of tropical medicine, ISSN 1995-7645, 2012, Volume 5, Issue 6, pp. 485 - 497
... subcontinents.New drug formulations like amphotericin B,its lipid formulations,and miltefosine have shown great efGcacy to treat leishmaniasis but their high cost and therapeutic complications limit... 
Drug | Drugs | Leishmaniasis | targets | resistance | Drug targets | Drug resistance | PROTOZOAN PARASITE LEISHMANIA | TRYPANOSOMA-CRUZI | THYMIDYLATE SYNTHASE | AMPHOTERICIN-B | TROPICAL MEDICINE | PROGRAMMED CELL-DEATH | CUTANEOUS LEISHMANIASIS | PENTAVALENT ANTIMONY | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | DIHYDROFOLATE-REDUCTASE | PENTAMIDINE RESISTANCE | VISCERAL LEISHMANIASIS | Antigens, Protozoan - immunology | Humans | Pentamidine - therapeutic use | Polyamines - antagonists & inhibitors | Phosphorylcholine - analogs & derivatives | Sterols - biosynthesis | Folic Acid Antagonists - therapeutic use | Mitogen-Activated Protein Kinase Kinases - metabolism | Sulfhydryl Compounds - metabolism | Topoisomerase Inhibitors - therapeutic use | Leishmaniasis - enzymology | Cyclin-Dependent Kinases - antagonists & inhibitors | Protease Inhibitors - therapeutic use | Macrophages - immunology | Microbodies - enzymology | Paromomycin - therapeutic use | Drug Discovery - trends | Leishmaniasis - drug therapy | Caspase Inhibitors | Enzyme Inhibitors - therapeutic use | Polyamines - metabolism | Amphotericin B - therapeutic use | Antimony Sodium Gluconate - therapeutic use | Antiprotozoal Agents - therapeutic use | Aminoquinolines - therapeutic use | Phosphorylcholine - therapeutic use
Journal Article